Sepsis drug
Total Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
349
NCT02991508
Adrecizumab Phase 1 Trial
Phase: Phase 1
Role: Collaborator
Start: May 23, 2016
Completion: Sep 22, 2016
NCT03083171
Adrecizumab-LPS Study
Role: Lead Sponsor
Start: Jan 4, 2017
Completion: May 24, 2017
NCT03085758
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
Phase: Phase 2
Start: Dec 12, 2017
Completion: Dec 20, 2019
Loading map...